RBA Wealth Management’s AstraZeneca AZN Stock Holding History

RBA Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-32	Closed	-$3.19K	–	44
2021 Q1	$3.19K	Buy	+32	New	+$3.22K	﹤0.01%	183

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RBA Wealth Management's AZN Position: Q2 2021 in Review

RBA Wealth Management sold out of AstraZeneca (AZN) in Q2 2021, closing a stake of 32 shares — an estimated $3.19K sold.

RBA Wealth Management first reported a position in AZN in Q1 2021 and held it in 1 quarter. The position peaked at $3.19K in Q1 2021. 768 funds tracked by Wall St. Rank hold AZN as of Q2 2021.

RBA Wealth Management reported no remaining AstraZeneca position as of Q2 2021 after selling out during the quarter.
RBA Wealth Management sold 32 AstraZeneca shares in Q2 2021, an estimated $3.19K.
RBA Wealth Management first reported a position in AstraZeneca in Q1 2021 and held it in 1 quarter.
RBA Wealth Management's AstraZeneca position peaked at $3.19K in Q1 2021.
768 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2021.

Based on RBA Wealth Management's 13F filing for Q2 2021, filed 22 Jul 2021.